Jarkko Kalliomäki

MD, Clinical lead and CMO

Role in PharmNovo: Clinical lead and CMO

Born: 1959.

Education: M.D. with specialization in Rehabilitation Medicine and Pain Medicine.

Ph.D. in physiology, Lund University.

Other current appointments: Senior Consultant Physician, part time, at different multidisciplinary pain and rehabilitation clinics in Stockholm (Sophiahemmet, ReAct Rehab, and PBM).

Work experience: Jarkko has over 30 years of experience in the pain field, including basic and clinical pain research, senior roles at several multidisciplinary pain clinics and 12 years of experience from the pharma industry as principal scientist and senior clinical research physician at AstraZeneca R&D Södertälje. working mainly with analgesic drug development.

Holdings: None.

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.